“Evaluation of 2-(4-Chlorophenyl)-4-(4-Fluorophenyl)-5-Pyridin-4-Yl-1,2-Dihydropyrazol-3-One As a p38 MAPK Inhibitor in MCF-7 and MDA-MB-231 Breast Cancer Cell Lines”. Al Mustansiriyah Journal of Pharmaceutical Sciences, vol. 25, no. 3, Aug. 2025, pp. 317-26, https://doi.org/10.32947/ajps.v25i3.1224.